Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
01/09/2026 23:04
BRIEF-Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia Sept 1 (Reuters) - Knight Therapeutics Inc GUD.TO:
KNIGHT THERAPEUTICS ANNOUNCES REGULATORY APPROVAL OF TAVALISSE® IN COLOMBIA
KNIGHT THERAPEUTICS - EXPECTS TAVALISSE LAUNCH IN COLOMBIA IN FIRST HALF OF 2027
Source text: ID:nGNX3Crnyb
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil